(Q28270780)

English

Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials

scientific article

Tolerability and Safety of Ropinirole versus Other Dopamine Agonists and Levodopa in the Treatment of Parkinsonʼs Disease

In more languages

Statements

scholarly article

0 references

1 reference

based on heuristic

inferred from title

1 reference

Europe PubMed Central

Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials (English)

0 references

Tolerability and Safety of Ropinirole versus Other Dopamine Agonists and Levodopa in the Treatment of Parkinsonʼs Disease (English)

1 reference

DOI.org query endpoint

https://doi.org/10.2165%2F11319860-000000000-00000

27 March 2017

Parkinson's disease

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Jaime Kulisevsky

1

object named as

Jaime Kulisevsky

1 reference

DOI.org query endpoint

27 March 2017

Javier Pagonabarraga

2

object named as

Javier Pagonabarraga

1 reference

DOI.org query endpoint

27 March 2017

language of work or name

0 references

publication date

1 February 2010

0 references

February 2010

1 reference

DOI.org query endpoint

https://doi.org/10.2165%2F11319860-000000000-00000

27 March 2017

2 references

DOI.org query endpoint

https://doi.org/10.2165%2F11319860-000000000-00000

27 March 2017

33

1 reference

DOI.org query endpoint

https://doi.org/10.2165%2F11319860-000000000-00000

27 March 2017

2

1 reference

DOI.org query endpoint

https://doi.org/10.2165%2F11319860-000000000-00000

27 March 2017

147-61

0 references

147-161

1 reference

DOI.org query endpoint

https://doi.org/10.2165%2F11319860-000000000-00000

27 March 2017

https://scigraph.springernature.com/pub.10.2165/11319860-000000000-00000

0 references

Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group.

1 reference

https://api.crossref.org/works/10.2165%2F11319860-000000000-00000

21 January 2018

Low dosages of bromocriptine added to levodopa in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.2165%2F11319860-000000000-00000

21 January 2018

Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group

1 reference

https://api.crossref.org/works/10.2165%2F11319860-000000000-00000

21 January 2018

A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of bromocriptine on parkinsonism. A nation-wide collaborative double-blind study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dopaminagonists and fibrotic valvular heart disease: further considerations

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ropinirole: a dopamine agonist for the treatment of Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recent developments in the pharmacological treatment of Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Transdermal Rotigotine

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of the Risk of Adverse Events with Pramipexole and Ropinirole in Patients with Parkinson???s Disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6-month interim report of a 3-year study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremor

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pramipexole in patients with early Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacoeconomic applications of meta-analysis for single groups using antifungal onychomycosis lacquers as an example

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pramipexole in levodopa-treated Parkinson disease patients of African, Asian, and Hispanic heritage

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Models of Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fibrotic valvular heart disease is not related to chemical class but to biological function: 5-HT2B receptor activation plays crucial role

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson's disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Measuring inconsistency in meta-analyses

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, double‐blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pramipexole-induced somnolence and episodes of daytime sleep

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative tolerability of the newer generation antiparkinsonian agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second generation of dopamine agonists: pros and cons.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A controlled trial of rotigotine monotherapy in early Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diagnosis and management of pergolide-induced fibrosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of Parkinson's disease with pergolide: a double-blind study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ropinirole for the treatment of early Parkinson disease: a 12-month experience. Ropinirole Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20082541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/11319860-000000000-00000

2 references

DOI.org query endpoint

https://doi.org/10.2165%2F11319860-000000000-00000

27 March 2017

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Dimensions Publication ID

0 references

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28270780&oldid=1644891951"